Introduction:
The biologics market in China is experiencing rapid growth, driven by increasing investment in research and development, as well as a growing demand for innovative therapies. According to industry reports, the biologics market in China is expected to reach $10 billion by 2026, making it one of the top markets in the world for biologic drugs.
Top 10 Biologics Knockout Models in China 2026:
1. Roche Holding AG: Roche is a leading biopharmaceutical company with a strong presence in China. The company’s biologics portfolio includes blockbuster drugs such as Rituxan and Herceptin, which have been highly successful in the Chinese market.
2. Novartis International AG: Novartis is another key player in the Chinese biologics market, with a focus on innovative therapies for diseases such as cancer and autoimmune disorders. The company’s biologics division has seen significant growth in recent years, with a number of new product launches driving sales.
3. Johnson & Johnson: Johnson & Johnson is a major player in the global biologics market, with a strong presence in China. The company’s biologics portfolio includes drugs such as Remicade and Stelara, which have been well-received by Chinese patients.
4. Pfizer Inc.: Pfizer is a leading pharmaceutical company with a growing presence in the Chinese biologics market. The company’s biologics division has seen strong growth in recent years, driven by the success of drugs such as Xeljanz and Inflectra.
5. Amgen Inc.: Amgen is a key player in the global biologics market, with a focus on innovative therapies for cancer and other serious diseases. The company’s biologics portfolio includes drugs such as Neulasta and Enbrel, which have been successful in the Chinese market.
6. AbbVie Inc.: AbbVie is a leading biopharmaceutical company with a strong presence in China. The company’s biologics division has seen significant growth in recent years, with drugs such as Humira and Imbruvica driving sales in the Chinese market.
7. AstraZeneca PLC: AstraZeneca is a major player in the global biologics market, with a growing presence in China. The company’s biologics portfolio includes drugs such as Tagrisso and Lynparza, which have been well-received by Chinese patients.
8. Merck & Co., Inc.: Merck is a leading pharmaceutical company with a strong presence in the Chinese biologics market. The company’s biologics division has seen strong growth in recent years, driven by the success of drugs such as Keytruda and Gardasil.
9. Bristol-Myers Squibb Company: Bristol-Myers Squibb is a key player in the global biologics market, with a focus on innovative therapies for cancer and other serious diseases. The company’s biologics portfolio includes drugs such as Opdivo and Yervoy, which have been successful in the Chinese market.
10. Biogen Inc.: Biogen is a leading biopharmaceutical company with a growing presence in China. The company’s biologics division has seen significant growth in recent years, with drugs such as Spinraza and Tecfidera driving sales in the Chinese market.
Insights:
The biologics market in China is poised for continued growth in the coming years, driven by increasing investment in research and development, as well as a growing demand for innovative therapies. According to industry forecasts, the biologics market in China is expected to grow at a CAGR of 15% between 2021 and 2026, reaching a value of $10 billion by the end of the forecast period. With the top 10 biologics knockout models leading the way, China is set to become a key player in the global biologics market in the years to come.
Related Analysis: View Previous Industry Report
